Biovaxys Technol Stock Price, News & Analysis

BioVaxys Technology Corp. announced that WuXi Biologics has successfully synthesized recombinant SARS-CoV-2 s-protein for its COVID-19 vaccine candidate BVX-0320 and the CoviDTH immunodiagnostic product. Both products are set for clinical trials, with an IND submission to the FDA for CoviDTH underway. The company has confirmed high yields of the protein, essential for clinical studies, while the FDA noted that a preclinical animal toxicity study is not mandatory for IND submission. BioVaxys continues this study for additional data.

BioVaxys Technology Corp. announced that Dr. Yvelise Barrios presented a study on the durability of T-cell responses to SARS-CoV-2 at the European Congress of Immunology. The study indicates that the DTH response, the basis for BioVaxys' CoviDTH diagnostic tool, can last over a year post-infection. Results showed significant DTH responses in two patients at both six and twelve months. BioVaxys aims to advance its vaccine development, awaiting an IND for a planned Phase I/II study in the US. The DTH test could serve as a routine method for monitoring T-cell immunity.

BioVaxys Technology Corp. has successfully closed the second tranche of its non-brokered private placement, raising approximately $1,176,880 by issuing 5,349,455 units at $0.22 each. Combined with the first tranche completed on July 14, 2021, total proceeds amount to $2,015,555. Each unit comprises one common share and a warrant exercisable at $0.50 for 30 months. The company plans to utilize these funds for research and development and working capital, subject to a four-month hold period for the issued securities.

BioVaxys Technology Corp. announced a non-brokered private placement of up to 9,090,909 units at $0.22 per unit, aiming for total proceeds of approximately $2,000,000. Each unit comprises one common share and a warrant, exercisable for an additional share at $0.50 within 30 months. Proceeds will support research and development and working capital. The closing is pending Canadian Securities Exchange approval and is expected within a week. BioVaxys is focused on developing vaccines and diagnostic technologies for COVID-19 and cancer.

BioVaxys Technology Corp. announced the appointment of Dr. Charles J. Dunton as an Advisor to enhance scientific support for its ovarian cancer vaccine candidate BVX-0918A and the marketing of Papilocare in the U.S. Dr. Dunton, a gynecologist/oncologist with over 30 years of experience, has collaborated with BioVaxys on early clinical trials and is recognized as one of America's Top Doctors for Cancer. The decision aims to advance clinical studies and marketing efforts, reinforcing BioVaxys's strategy in the competitive immuno-oncology market.

BioVaxys Technology Corp. (CSE: BIOV, OTC: BVAXF) announced the appointment of Dr. Adam Coutts as Policy Advisor, effective May 20, 2021. Dr. Coutts, a Senior Research Fellow at the University of Cambridge, specializes in public health policy. CEO James Passin stated that Dr. Coutts' expertise will be crucial in advancing CoviDTH, a novel skin test for T cell immunity to Covid-19, through regulatory and commercial pathways. This low-cost solution aims to aid health systems in vulnerable settings, thereby optimizing vaccine distribution.

BioVaxys Technology Corp. (OTCQB: BVAXF) has announced its uplisting from the OTC Pink Sheets to the OTCQB Venture Market as of May 19, 2021. This mid-tier market is designed for early-stage companies, enhancing the visibility and liquidity of BioVaxys shares. CEO James Passin emphasized that this move will improve access to capital for the company's ongoing development of vaccines for ovarian cancer and COVID-19 diagnostics. BioVaxys currently has two issued patents and plans further clinical trials.

BioVaxys Technology Corp. announced a definitive bioproduction agreement with BioElpida S.A.S. for clinical-grade bioproduction of its ovarian cancer vaccine candidate, BXV-0918A. The agreement focuses on building a GMP facility in Lyon, France, and includes critical technical protocols. BioVaxys plans to submit a regulatory filing for a Phase I study by late 2021, with vaccine supply ready by May 2022. The ovarian cancer market is projected to grow from US$1.2B in 2017 to US$4.6B by 2026, indicating a strong need for innovative treatments in this area.

BioVaxys Technology Corp. (OTC: BVAXF) announced it has filed an intent-to-use trademark application for CoviDTH®, a T-cell immune response diagnostic for SARS-CoV-2. This move aims to secure a distinctive mark as the product approaches the market. Additionally, BioVaxys broadened its intellectual property by filing an international patent application via the Patent Cooperation Treaty for its bihaptenized tumor antigen vaccine platform, covering various cancers, including cervical and ovarian cancer. The company continues to strengthen its vaccine development initiatives.